The effects of magnetic nanoparticle properties on magnetic fluid hyperthermia I. INTRODUCTION
Cancer is a leading cause of human deaths.
1,2 Current treatments, such as surgery and chemotherapy, can have undesirable side effects, including harm to the surrounding healthy tissue. Hyperthermia is an alternative treatment that can destroy cancerous cells by significantly elevating the temperature of tumor cells while keeping that of the surrounding healthy tissue at a reasonable level. 3 One method to induce hyperthermia is by use of ferrofluids, which are colloidal suspensions of magnetic nanoparticles ͑MNPs͒ in a nonpolar medium. These fluids can be magnetically targeted to cancerous tissue after intravenous application. 1 The magnetic particles extravasate into the tumor due to the high microvascular permeability and interstitial diffusion in neoplastic tissue. 4 Thereafter, the MNPs are heated by exposing the tumor to a high frequency alternating magnetic field, causing thermonecrosis of the embedding tissue. This process is called magnetic fluid hyperthermia ͑MFH͒. 3, [5] [6] [7] [8] [9] In order to examine the potential of hyperthermia as a viable alternative to chemotherapy and radioactive treatment, it is necessary to define what such a treatment would hope to accomplish. Temperatures in the range of 41-45°C are enough to slow or halt the growth of cancerous tissue, but such heating can also damage healthy cells. 3 Thus, an ideal hyperthermia treatment should sufficiently increase the temperature of the tumor cells while maintaining the healthy tissue temperature below 41°C. Ferrofluid-based thermotherapy can be also accomplished through thermoablation, which typically heats tissues up to 56°C to cause their necrosis, coagulation, or carbonization by exposure to a noninvasive radio frequency ac magnetic field. 5 Local heat transfer from the nanoparticles increases the tissue temperature and ruptures the cell membranes. 10, 11 Iron oxide nanoparticles such as magnetite, or its oxidized form maghemite, are the most biocompatible agents for MFH. 9 These particles are typically coated with a biocompatible polymer to prevent their aggregation and biodegradation for in vivo applications. Platinum and nickel are also MNPs but are toxic and vulnerable to oxidation.
2
MFH employing fine magnetic particles was first investigated by Gilchrist et al. 12 This work was followed by several in vitro and in vivo experiments to confirm the feasibility of magnetic particle use for MFH. 11, [13] [14] [15] Numerical investigations have also allowed researchers to understand and improve MFH therapy in soft biological tissue by using models consisting of multiple homogeneous regions 16 that contain tumor and normal tissue. 15, 17, 18 These models have provided approaches for the proper particle dosage and distribution in the tumor, and the optimal particle properties and magnetic field strengths that minimize the side effects of MFH on healthy tissues. For optimal MFH treatment, ferrofluid dosage should be minimal and yet provide sufficient heating. This depends upon factors such as the magnetic anisotropy constant of the nanoparticles, and the strength and frequency of the ac field. Previous investigations have considered specific ferrofluids to determine the optimal particle type and size 5, 9, 19 and the thermal response of tissue. 7 However, the literature does not provide guidance about the influence of both particle type and size on MFH under typical clinical conditions. There-fore, we focus on the appropriate use of MNPs to heat soft tissue using an ac magnetic field 9 in this context. When exposed to such an ac field, the MNPs dissipate magnetic energy into heat through both Brownian and Néel relaxations. Besides the strength and frequency of the alternating magnetic field, 20 the magnetic properties of an MNP also play an important role in heat generation and dissipation. 9, 19 We account for the particle size distribution, saturation magnetization, and the material anisotropy constant. Since iron nanoparticles have both a large saturation magnetization 21 and a high Curie temperature ͑of 1043 K͒, 21 we consider iron and iron compound nanoparticles as primary choices for MFH. 9, 19 Changing the nanoparticle size can significantly alter the ability of an MNP to generate heat, 9, 22 making the determination of an optimum nanoparticle size necessary for a specified set of conditions.
Here, we present a thermodynamic analysis of ferrofluid magnetic heating and compare the performance of six different types of ferrofluids, namely those containing magnetite ͑FeO· Fe 2 O 3 ͒, maghemite ͑␥-Fe 2 O 3 ͒, iron-platinum ͑FePt͒, iron-cobalt ͑FeCo͒, barium-ferrite ͑BaFe 2 O 4 ͒, and cobaltferrite ͑CoFe 2 O 4 ͒. We examine their performance for different magnetic field strengths, frequencies and particle radii. Thereafter, we investigate the heating of a tumor and the surrounding healthy tissue with suitable MFH ferrofluid candidates.
II. ANALYSIS OF MAGNETIC HEATING

A. Thermodynamic analysis
For a constant density system and an adiabatic process,
͑1͒
where dU denotes the internal energy change, ␦Q the heat input, ␦W the work done on the system, H ជ the magnetic field intensity, and B ជ the magnetic field. Upon integration,
Here, 0 denotes the permeability of free space and M the magnetization of the material. Since an oscillating magnetic field is required to produce the Brownian and Néel relaxations during MFH, we assume that
Using the Langevin equation 23 the magnetization of the nanoparticles
where M sat denotes saturation magnetization of the material. The Langevin parameter L͑t͒ is defined as
where R is the nanoparticle radius, k the Boltzmann constant ͑1.38ϫ 10 −23 J K −1 ͒, and T the absolute temperature ͑Kelvin͒. The ferrofluid susceptibility
where Ј and Љ denote the real and imaginary components of the complex ferrofluid susceptibility = Ј − iЉ. Here, refers to the relaxation time of the ferrofluid that is dependent on its material properties, and the angular frequency of the ac magnetic field. Thus, the particle magnetization
Substituting Eq. ͑7͒ into Eq. ͑2͒,
The power dissipation, P, due to magnetic heating is the product f⌬U, i.e.,
where f = / 2.
B. Parametric investigation
We now investigate the influence of H 0 , f, and R on MFH by assuming a lumped ferrofluid dosed tissue system. Its temperature variation 9 dT/dt = P/͑c͒, ͑10͒
where and c denote the ferrofluid density and heat capacity, respectively. Equation ͑10͒ is expressed in terms of a nondimensional temperature rise parameter
where T i denotes the initial temperature, ␣ the thermal diffusivity of the tumor, and the ‫ء‬ stands for nondimensional parameter. The Joule number J represents the ratio of the heating energy to the magnetic field energy, t ‫ء‬ is a normalized time, and F 0 the Fourier number defined as
shows that the rate of change in ferrofluid temperature depends inversely on J. Hence, if the material and the particle size are specified and the frequency is held constant, ͑dT / dt͒ ‫ء‬ varies quadratically with H 0 . Next, we examine the behavior of t ‫ء‬ / F 0 for a representative MNP radius R = 5 nm, ␣ = 0.132 mm 2 / s, determined from the material properties in Table I , 19 and an MNP volume fraction =2ϫ 10 −4 . The initial tumor temperature T i is assumed to be 37°C. Figure 1 shows that t ‫ء‬ / F 0 , thus dT / dt, varies qua- dratically with the frequency when the field strength, i.e., J, is held constant. Therefore, MFH treatment is more effective at higher magnetic field strengths and frequencies with the limitation that high frequencies and strong magnetic fields can cause significant adverse affects on the human body above a maximum threshold.
C. Heating profiles of different ferrofluids
The power dissipation from a nanoparticle depends upon its magnetic susceptibility, which in turn is related to the ferrofluid relaxation time. Brownian relaxation occurs when the particle spins to align itself with the magnetic moment, while Néel relaxation occurs when the magnetic moment spins within the crystal structure of the nanoparticle, 9 where
where denotes the viscosity of the matrix fluid, ␦ the thickness of surfactant layer, 0 the Larmor time constant ͑=1 ϫ 10 −9 s͒, and the anisotropy constant. Both the Brownian and Néel relaxation times, denoted, respectively, by B and N , influence the total relaxation time of the particle, i.e.,
We note from Eqs. ͑5͒, ͑13͒, and ͑14͒ that both M sat and , which are material properties, contribute to the dissipated power. Therefore, we employ Eq. ͑10͒ to simulate the heating rates with different materials of varying particle sizes.
The maximum safe field strength that can be applied to humans is 15 kA/m. 3 For this reason, the simulated field strengths are specified to be 5, 10, and 15 kA/m. Frequencies of 150, 300, and 450 kHz are simulated to maintain the product H • f below the maximum threshold value of 4.85 ϫ 10 10 kA turns/ ͑m s͒ allowable for humans. 24 Figures 2 and 3 show that higher frequencies and magnetic field strengths induce greater hyperthermia. However, taking patient safety into account, only values in the middle range of both the frequency and field strength are further investigated ͑i.e., 300 kHz and 10 kA/m, respectively͒.
‫ء‬ on the frequency of the magnetic field for a constant J. The MNP radius R = 5 nm, ␣ = 0.132 mm 2 / s with tissue properties as described in Table I. FIG. 2. Rate of change in temperature with respect to MNP radius for different H 0 and a constant 300 kHz magnetic field frequency for different MNP materials: ͑a͒ magnetite, ͑b͒ maghemite, ͑c͒ iron-platinum, ͑d͒ iron-cobalt, ͑e͒ barium-ferrite, ͑f͒ cobalt-ferrite.
D. Influence of nanoparticle radius
As seen from Eqs. ͑13͒ and ͑14͒, the nanoparticle size also plays an important role in determining the amount of heating that an MFH treatment can provide. Figures 2 and 3 show that each material has a critical radius for which dT / dt is maximum. This radius is recorded in the last column of Table II for the various materials. MNPs made of BaFe 2 O 4 and CoFe 2 O 4 , are not suitable for MFH, since the maximum rate of temperature change for these materials is far too low. FeCo MNPs produce temperature changes that are too rapid to be safe for inducing controlled MFH. The remaining three MNPs are capable of producing reasonably rapid, yet controlled, temperature changes. Therefore, we examine the interaction of these latter three candidate materials with biological tissue.
We also consider the range of polydispersion that each type of material allows. Figures 2 and 3 show that some materials provide significant heating over a wider range of nanoparticle sizes than others do. For instance, large rates of temperature change occur over a wider range of radii for fcc FePt than for magnetite and maghemite. Defining T 1/2 Ј as half of the maximum value of dT / dt, the range of nanoparticle sizes that produce a temperature change rate greater than or equal to T 1/2 Ј are reported in Table III for H 0 =10 kA/ m and f = 300 kHz.
For BaFe 2 O 4 , CoFe 2 O 4 , and fcc FePt, the induced temperature change rate is a reasonable fraction of the maximum temperature change over a range of over 5 nm. However, materials such as magnetite ͑FeO· Fe 2 O 3 ͒ and maghemite ͑␥ ·Fe 2 O 3 ͒ have a much smaller size range ͑Ϸ1.6 nm͒. This indicates that if magnetite and maghemite were to be used for MFH, the MNPs would have to be more monodisperse for adequate heating to occur while an MFH treatment using fcc FePt could allow for a larger polydisperse range of particle sizes.
III. ANALYSIS OF TISSUE HEATING IN MFH
A. Tumor model
Having identified the factors that influence the heating of different MNPs, we now examine tissue heating in an MFH FIG. 3 . Rate of change in temperature with respect to MNP radius for different magnetic field frequencies and constant H 0 =10 kA/ m for different MNP materials: ͑a͒ magnetite, ͑b͒ maghemite, ͑c͒ iron-platinum, ͑d͒ iron-cobalt, ͑e͒ barium-ferrite, ͑f͒ cobalt-ferrite. application for the idealized geometry of a spherical tumor tissue shown in Fig. 4 . The tumor is selectively loaded with MNPs while the healthy tissue surrounding it contains no nanoparticles. A perfusion term considers heat transfer to the blood as being proportional to the volumetric blood flow and the difference between the local tissue and the arterial temperatures. 25, 26 The blood temperature is always 37°C, a reasonable assumption since it travels rapidly enough to be relatively unaffected by any heating. 27 The blood perfusion is homogeneous throughout the healthy and affected tissue, since blood capillaries are typically homogeneously distributed in the tissue bed. 28 The MNP-loaded tissue experience a volumetric heating under an alternating magnetic field, while the perfusing blood abstracts heat from the tissue as long as the tissue temperature is above a threshold ͑the basal body temperature͒. In order to determine the heating of biological tissue, we use a mathematical model based on the Pennes bioheat transfer equation, 19 i.e.,
where r denotes the radial distance, the thermal conductivity, w b the blood perfusion, q met metabolic heat generation ͑taken as 540 W͒, and the subscripts 1, 2, and b stand for tumor tissue loaded with MNPs, tumor tissue without MNPs, and blood, respectively. The values for 2 and c 2 are provided in Table I while 1 = ͑1−͒ 2 + and c 1 = ͑1−͒c 2 + c, where and c, respectively, denote the density and heat capacity of the nanoparticle being used. As illustrated in Fig.  4 , r a denotes the radius of the region of tumor tissue loaded with MNPs, and r o the domain of the model. The inner boundary condition for Eq. ͑16͒ is imposed through a zero temperature gradient due to spherical symmetry at r =0. A convection heat balance boundary condition is imposed at the interface of the edge of the healthy tissue at r = r o . An initial condition that assumes a uniform temperature distribution equal to the arterial blood temperature ͑37°C͒, precedes the application of the alternating magnetic field. A finite difference scheme is used to solve Eqs. ͑16͒ and ͑17͒. The solution methodology is described in Appendix. The simulation is conducted with a homogeneous grid of 500 cells, which provides grid independent results.
B. Influence of nanoparticles material on tumor heating
Simulations are conducted with identical loadings ͑ = 0.02%͒ of the three different nanoparticle materials. The material properties for the tissue are described in Table I and those for the MNPs required to determine P are taken from several sources in the literature and listed in Table II . 9, 19, 29 We assume that the MNPs are monodispersed and have a size equal to the critical radius at which dT / dt is maximum ͑as discussed in Sec. II D; the radius R is reported in Table  II͒ , that the imposed magnetic field has a strength of H =10 kA/ m and a frequency of f = 300 kHz, the ferrofluid has a viscosity of 6.53ϫ 10 −4 Pa s at 37°C, and the surfactant thickness is 1 nm. 17 Each simulation is performed until the tissue temperature reaches a steady state. For the sake of illustration, r a = 1 cm while r o = 10 cm. A steady blood infusion rate of 6.4 s −1 is assumed for all the simulations. 
Magnetite
The material constants for magnetite 9 in Table II are used to obtain the results shown in Figs. 5 and 6 . The temporal evolution of the tumor center temperature presented in Fig. 5 shows a rapid initial increase which soon stabilizes to a nearly constant value. The maximum temperature reached by magnetite particles is slightly greater than 47°C at the tumor center, which is well above the minimum required temperature required for MFH. Figure 6 shows that the temperature at r = 1 cm, i.e., at the tumor-healthy tissue interface, reaches a maximum value of Ϸ40°C. This implies that while almost all of the tumor tissue can be subjected to hyperthermia, no healthy tissue will be damaged, since the temperatures lie below 41°C for r Ͼ 1 cm. Table II .
Iron-platinum
The material properties for fcc FePt are obtained from the literature. 19 Figure 5 shows that the temperature increase during MFH with fcc FePt is significantly more rapid than with magnetite. However, the eventual steady state temperatures are almost equivalent even though FePt produces slightly higher heating. At the tumor center, the temperature rises to above 60°C while it is Ϸ47°C at the tumor-healthy interface. The temperature falls below 41°C a short distance of 1.28 cm removed from the interface into the healthy tissue. This has the unintended consequence of harming a small section of the surrounding tissue along with the tumor cells. Figure 5 shows that maghemite MNPs induce slightly slower heating of the tissue than with magnetite. At the tumor center, the temperature increases to just above 47°C. The temperature at the tumor-healthy interface is Ϸ41°C. This is promising since all of the tumor cells reach a high enough temperature to induce hyperthermia while the surrounding healthy tissue is preserved.
Maghemite
C. Effects of tumor size
While these results, especially those for magnetite and fcc FePt, are in good agreement with some literature, 19 other investigations indicate that the temperature increases for these cases might be much smaller. 30 In order to reconcile these differences, we simulate MFH for a smaller tumor with r a = 5 mm but keeping the other conditions the same. Figures  7 and 8 show the corresponding temporal growth of the tissue center temperature, and the steady state temperature distribution, respectively. Since the tumor radius is now half its previous value, the number of nanoparticles it contains decreases by an eighth. This produces significantly lower heating, which is evident by comparing Figs. 5 and 7 or Figs. 6 and 8. In Fig. 7 , the tumor center temperature increases at a slower rate for all the three nanoparticles.
However, a quasisteady state is reached sooner for the 5 mm radius tumor than its 10 mm counterpart. Comparison of Figs. 7 and 8 indicates that the temperatures both at tumor center and tumor-healthy tissue interface are lower for the 5 mm radius tumor.
The simulations indicate that tumor size has a significant effect on the ability of MNPs to heat cancerous tissue. While iron-platinum is still capable of producing hyperthermia for the smaller radius tumor, neither magnetite nor maghemite produce enough heating for the tumor-healthy interface to reach 41°C. The temperature at the tumor-healthy interface is presented in Fig. 9 for a range of tumor radii. Ironplatinum produces hyperthermia at tumor sizes of 5 mm or larger but magnetite and maghemite require tumor sizes of 11 mm and 10 mm, respectively, in order to effectively expose all of the cancer cells to MFH. To treat tumor sizes smaller than 5 mm would require an increase in the ferrofluid volume fraction, since increasing the magnetic field strength or frequency might lead to unsafe conditions for the patient. Although the number of nanoparticles varies as r 3 for specified , the effect of changing radius on the temperature at the tumor-healthy interface does not scale similarly above r = 3 mm. As both the interface and average tumor temperatures increase, the heat loss from the tumor due to blood perfusion also increases. Thus, as the tumor radius becomes larger than 3 mm, the increase in the interface temperature is more gradual with increasing tumor size, as shown in Fig. 9 .
In order to distinguish whether the enhanced heating is related to an increase in tumor size or occurs simply due to a larger number of nanoparticles, we simulated MFH for tumors with different radii and magnetite nanoparticle volume fractions. These results are shown through the contour plots in Fig. 10 for tumor radii in the 0-30 mm range and particle volume fractions of 0%-0.04%. The vertical dotted line in Fig. 10 represents the condition for magnetite particles described in Fig. 9 . The interface temperature becomes less sensitive to larger tumor radii, which is consistent with Fig.  9 , although the temperature always increases with increasing radius.
This loss of sensitivity of the interfacial temperature to tumor size is attributed to the increased perfusion heat loss for larger tumors, which is also more significant for smaller nanoparticle loading. For example, when the particle loading is lower than 0.005%, the tumor-healthy tissue interface temperature is virtually insensitive to increasing tumor radius when r a Ͼ 0.8 cm. To raise this temperature for larger tumors, must be increased. However, increasing for smaller tumors does not follow a similar trend. The implication is that it is not possible to induce hyperthermia in tumors that are exceedingly small. Figure 10 is useful as a quick guide to select suitable particle loadings that will heat a tumor of a particular size optimally. Combinations of and r a selected from Fig. 10 provide optimal MFH conditions, i.e., when only the tumor is treated and no healthy tissue is damaged.
IV. CONCLUSIONS
We investigated the thermal response of six ferrofluid materials, magnetite, maghemite, fcc iron-platinum, ironcobalt, barium-ferrite, and cobalt-ferrite, on a tissue undergoing MFH. Iron-cobalt MNPs induce temperature changes that are too large, whereas barium-ferrite and cobalt-ferrite MNPs do not provide enough heat to treat a tumor. The heating from MNPs dissipates within a relatively small distance from the center of a perfused tumor, which can be used advantageously to preserve the surrounding healthy tissue. Our simulations show that magnetite, fcc iron-platinum, and maghemite MNPs are well suited for MFH, making it possible to heat tumors above 41°C while keeping the surrounding healthy tissue temperatures below this value. The temperature at the tumor-healthy tissue interface falls below the threshold value for small tumor radii, which require larger MNP volume fractions for successful MFH. The tumor surface temperature increases as r a 3 for small tumors but this rate of increase declines at larger radii due to the more pronounced heat loss through blood perfusion.
APPENDIX
Since metabolic heat generation q met is much smaller than the other terms in the governing equations ͑roughly 540 W over the entire human body͒, 19 we neglect its effects. The boundary conditions to the partial differential equations are zero gradient at the center and a convection heat transfer at r = r o , while the initial condition is a uniform temperature distribution equal to the arterial blood temperature ͑37°C͒.
In order to solve Eqs. ͑16͒ and ͑17͒ for T 1 and T 2 , we consider 2 ͑‫ץ‬T 2 /‫ץ‬r͉͒ r=r 0 + hT͑r 0 ,t͒ = hT ϱ .
͑A3͒
A central differencing scheme is used to discretize Eqs. ͑A1͒ and ͑A2͒ at every node, including the boundary nodes. The boundary condition of zero temperature gradient at r =0 is imposed by using a fictitious node and prescribing T −1 n = T 1 n in the discretized governing equation at r = 0. In order to avoid the singularity at r = 0, Eq. ͑A1͒ is replaced at r = 0 with Similarly, the far end ͑i.e., r = r o ͒ convective boundary condition ͓Eq. ͑A3͔͒ is specified using a fictitious cell after the farthest node. The discretized equation for any internal node ͑i.e., for 0 Ͻ r Ͻ r 0 ͒ is For r Ͼ r a , Eq. ͑A6͒ is rewritten by replacing all terms with a subscript 1 with the corresponding terms with subscript 2, and setting P =0. 
